Innovating Emergency Care | Peter O’Neill Discusses De Motu Cordis at JPM Week 2025
April 24, 2025
During the prestigious JPM Week 2025, held at San Francisco’s Golden Gate Yacht Club, Peter O’Neill, CEO of De Motu Cordis, engaged in a compelling conversation with James Zanewicz of Tulane University School of Medicine. This interview, part of the Bullpen series, highlighted the groundbreaking work of De Motu Cordis in revolutionizing emergency medical treatment.
About DMC
DMC is a clinical stage medtech company founded in Brisbane, Australia by globally recognised intensive care specialist, researcher, entrepreneur and founder Professor John Fraser AO.
DMC is developing a proprietary inhaled drug delivery platform for use in critical care emergencies. Our lead asset is an investigational inhaled epinephrine product to treat anaphylaxis.
DMC has a strong suite of intellectual property portfolio protecting both its inhaled drug delivery platform and therapeutic formulations. To date, DMC has raised more than AU$30 million from both private and public sector investors.
